Krishna Institute of Medical Sciences Limited ( Krishna Institute of Medical Sciences Limited ) will host a conference call with analysts and investors on Tuesday, August 4, 2026, at 10:00 am IST. The discussion will focus on the company’s business strategy and future outlook following the declaration of its Q1FY27 financial results. This engagement provides stakeholders with direct access to management for insights into operational performance and strategic direction.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was submitted to the Bombay Stock Exchange Ltd and the National Stock Exchange on July 28, 2026. The call is being hosted by IIFL Capital, which has circulated the invitation details to market participants.

Key management personnel scheduled to participate in the conference call include Dr. Bhaskara Rao Bollineni, Founder & Managing Director; Dr. Abhinay Bollineni, Executive Director & CEO; and Mr. Sachin Salvi, Chief Financial Officer. Their presence ensures that both strategic and financial aspects of the Q1FY27 performance will be addressed comprehensively.

The conference call is accessible via toll-free numbers for domestic and international participants. For India, the universal access numbers are +91 22 6280 1259 and +91 22 7115 8160. International participants can dial in from the USA (1-866 746 2133), UK (0-808 101 1573), Singapore (800-101 2045), and Hong Kong (800-964 448). A Diamond Pass registration is also available for enhanced access.

For further information regarding the conference call, investors may contact Rahul Jeewani, Naman Bagrecha, Aman Goyal, or Vighnesh Indure at IIFL Capital. The company secretary and compliance officer, Dr. Nagajayanthi J. R., signed the disclosure document, confirming the accuracy of the intimation.

Krishna Institute of Medical Sciences has approved the issuance of 77,02,182 warrants on a preferential basis to its promoters and a promoter group entity. The resolution was passed by shareholders at the Extraordinary General Meeting (EGM) held on July 9, 2026, through Video Conferencing and Other Audio Visual Means. The company also approved the re-designation of Mr. Adwik Bollineni as Executive Director for a period of five years.

Voting Results Summary

The scrutinizer's report confirms that all resolutions were passed with the requisite majority. The preferential issue of warrants to Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP received 94.32% votes in favour. The re-designation of Mr. Adwik Bollineni was approved with 82.32% votes in favour, with votes from interested parties treated as invalid.

Resolution Details

The following table summarizes the voting results for the key resolutions:

Procedural Details

The remote e-voting facility was open from July 6, 2026, to July 8, 2026. A total of 402 members participated in the voting process, representing 31,67,34,800 shares. Mr. Krishna Rao Inturi, Proprietor of IKR & Associates, served as the scrutinizer for the meeting. The results have been submitted to the BSE and NSE.